Literature DB >> 2737759

Association experiments with aerobic and anaerobic pathogens: a model of in-vitro susceptibility testing in mixed infections. Activity of enoxacin, clindamycin, and metronidazole.

W R Heizmann1, R Schmid, F Heilmann, H Werner.   

Abstract

In infections of polymicrobial etiology, it seems mandatory to combine an antibiotic with marginal activity against anaerobes with an anti-anaerobic drug, e.g. metronidazole or clindamycin. We investigated the effect of associations of anaerobic and facultatively anaerobic pathogens on MBCs of enoxacin, clindamycin, metronidazole, and combinations of enoxacin plus clindamycin or metronidazole. Single testing, and associations of Bacteroides fragilis with Escherichia coli or Enterococcus faecalis revealed MBCs of 64 mg/l for enoxacin. However, investigating metronidazole, MBCs for B. fragilis increased from 0.5-1 mg/l to 2-4 mg/l in association with E. coli. The combination of enoxacin with metronidazole restored MBCs of 0.5 and 1 mg/l for the B. fragilis strains. B. fragilis associated with E. faecalis showed MBCs of 2 to 64 mg/l for metronidazole, an increase of up to 64-fold. The enoxacin MBCs for E. coli in association with B. fragilis were up to eight-fold higher than for E. coli alone (2 mg/l compared to 0.25 mg/l). Association of E. coli with E. faecalis and B. fragilis showed a low to moderate increase for MBCs of E. coli when enoxacin was tested alone or in combination with metronidazole or clindamycin. In contrast, MBCs for E. faecalis did not change significantly with any of the associations or combinations tested. It is evident that in vitro antimicrobial susceptibility of associations of pathogens can be modified by interactions between strains, and/or antimicrobials.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737759     DOI: 10.1007/bf01644018

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Medium for use in antibiotic susceptibility testing of anaerobic bacteria.

Authors:  T D Wilkins; S Chalgren
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

2.  [In vitro activity of an ofloxacin-metronidazole combination against anaerobic bacteria. Kinetics of the action of metronidazole against Bacteroides fragilis].

Authors:  L Dubreuil; J Devos; H Beerens; C Romond
Journal:  Pathol Biol (Paris)       Date:  1988-05

3.  The activity of metronidazole against facultatively anaerobic bacteria.

Authors:  H R Ingham; C J Hall; P R Sisson; D Tharagonnet; J B Selkon
Journal:  J Antimicrob Chemother       Date:  1980-05       Impact factor: 5.790

Review 4.  Treatment of skin and skin structure infections in the patient at risk.

Authors:  J N Sheagren
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

Review 5.  Comparative activity of the 4-quinolones.

Authors:  I Phillips; A King
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

6.  Enoxacin distribution in human tissues after multiple oral administration.

Authors:  A S Malmborg; S Rannikko
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

7.  The in-vitro activity of metronidazole against Enterobacteriaceae alone and in mixed cultures with Bacteroides fragilis.

Authors:  F J Moran; C Perez; C Hurtado; M T Blanco; J Prieto
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

8.  Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.

Authors:  C Siporin; G Towse
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Quantitative aerobic and anaerobic bacteriology of infected diabetic feet.

Authors:  F L Sapico; H N Canawati; J L Witte; J Z Montgomerie; F W Wagner; A N Bessman
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

Review 10.  The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection.

Authors:  I Brook
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  9 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 2.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  [Enoxacin concentrations in serum and in the wall of the colon during colorectal surgery].

Authors:  M Wenzel; F Sörgel; P Muth; H Kraeft
Journal:  Infection       Date:  1989       Impact factor: 3.553

4.  [Susceptibility of clinically important Bacteroides species against enoxacin-metronidazole and enoxacin-clindamycin combinations].

Authors:  W R Heizmann; H Werner; R Schmid
Journal:  Infection       Date:  1989       Impact factor: 3.553

5.  In vitro activity of daptomycin-metronidazole combinations against mixed bacterial cultures: reduced activity of metronidazole against Bacteroides species in the presence of Enterococcus faecalis.

Authors:  E Nagy; H Werner; W Heizmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

Review 6.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.

Authors:  F Heilmann
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

8.  Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.

Authors:  W R Heizmann; F Heilmann; B Egeler; H Werner
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

Review 9.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.